AssetMark Inc’s Arcus Biosciences RCUS Stock Holding History

AssetMark Inc’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-43	Closed	-$338	–	3102
2025 Q1	$338	Buy	+43	New	+$499	﹤0.01%	2472

Other funds holding RCUS

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

AssetMark Inc's RCUS Position: Q2 2025 in Review

AssetMark Inc sold out of Arcus Biosciences (RCUS) in Q2 2025, closing a stake of 43 shares — an estimated $338 sold.

AssetMark Inc first reported a position in RCUS in Q1 2025 and held it in 1 quarter. The position peaked at $338 in Q1 2025. 185 funds tracked by Wall St. Rank hold RCUS as of Q2 2025.

AssetMark Inc reported no remaining Arcus Biosciences position as of Q2 2025 after selling out during the quarter.
AssetMark Inc sold 43 Arcus Biosciences shares in Q2 2025, an estimated $338.
AssetMark Inc first reported a position in Arcus Biosciences in Q1 2025 and held it in 1 quarter.
AssetMark Inc's Arcus Biosciences position peaked at $338 in Q1 2025.
185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2025.

Based on AssetMark Inc's 13F filing for Q2 2025, filed 4 Aug 2025.